MUNICH – Chidamide + exemestane combination therapy increased PFS by about 4 months, compared with exemestane...
Dr. Richard-Davis served as the Scientific Program Chair of the 2018 NAMS Meeting. In this audiocast she highlights several clinical takeaways...
MUNICH – Adding atezolizumab to nab-paclitaxel improved progression-free and overall survival in patients with PD-L1 positive triple-negative...
No. In a prospective study that followed 872 BRCA1 carriers after oophorectomy for a mean follow-up of...
Identifying patients who are appropriate candidates for breast cancer genetics testing is a key step toward prevention and value-based care
Oncologists say a new company that aims to link patients with cancer care and clinical trials through technology has both positives and negatives...